Oxygenta Pharmaceutical has announced significant changes in its leadership structure and promoter classification, signaling a shift in the company's ownership and management.

Key Leadership Changes

The pharmaceutical company reported the resignation of Mr. Vankineni Sai Sudhakar from his positions as Managing Director and Chief Financial Officer, effective August 18, 2025. In his resignation letter, Mr. Sudhakar cited the change in ownership and management of the company as the reason for his departure.

Additionally, Mr. Sanagari Kondal Reddy stepped down from his role as Independent Director on the same date, also attributing his resignation to the change in the company's management following a takeover.

Promoter Reclassification

In a significant move, Oxygenta Pharmaceutical's board approved the reclassification of four promoter group shareholders to public shareholders. This decision, subject to necessary approvals from stock exchanges and shareholders, affects the following individuals:

The reclassification request, dated August 19, 2025, is in accordance with Regulation 31A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Board Committee Restructuring

Following these changes, Oxygenta Pharmaceutical has reconstituted its board committees. The new structure of key committees is as follows:

Audit Committee

• Chairman: Sidda Reddy Kanuparthi (Additional Director - Independent)
• Members: Sharvari Swapnil Shinde, Veera Reddy Arava (both Additional Directors - Independent), and Chandra Mouliswar Reddy (Additional Director - Executive)

Nomination and Remuneration Committee

• Chairman: Veera Reddy Arava (Additional Director - Independent)
• Members: Sidda Reddy Kanuparthi and Sharvari Swapnil Shinde (both Additional Directors - Independent)

Annual General Meeting

The company has scheduled its Annual General Meeting for the financial year 2024-25 on September 19, 2025, to be held via video conferencing. M/s. Aakanksha Dubey & Co., Practicing Company Secretary, has been appointed as the scrutinizer for e-voting at the AGM.

These developments mark a significant transition period for Oxygenta Pharmaceutical, potentially indicating a new direction for the company under its changing ownership structure.

Oxygenta Pharmaceutical Limited, a prominent player in the pharmaceutical sector, has announced significant changes in its ownership structure and management. The company has received requests from four promoters seeking reclassification from the 'Promoter' category to the 'Public' category, signaling a potential shift in the company's control and governance.

Promoter Reclassification Requests

The four promoters who have submitted reclassification requests are:

1. Sai Sudhakar Vankineni: Holding 30,000 shares (0.08% of equity)
2. Snigdha Vankineni: Holding 5,43,000 shares (1.47% of equity)
3. Sumanth Simha Vankineni: Holding 3,43,700 shares (0.93% of equity)
4. Jhansi Rani Vankineni: Holding 26,000 shares (0.07% of equity)

In their applications, all four promoters have stated that they are not involved in the company's management, day-to-day affairs, or business operations. They have also confirmed that they do not have any rights to appoint directors or control management decisions.

Management Changes

Concurrent with the reclassification requests, Oxygenta Pharmaceutical has announced significant changes in its leadership:

1. Mr. Vankineni Sai Sudhakar has resigned from his positions as Managing Director and Chief Financial Officer, effective August 18, 2025.
2. Mr. Sanagari Kondal Reddy has stepped down from his role as Independent Director, also effective August 18, 2025.

Both resignations are attributed to changes in the ownership and management of the company, suggesting a broader restructuring effort.

Regulatory Compliance

Oxygenta Pharmaceutical has stated that it will undertake the necessary steps to comply with the reclassification process under SEBI regulations. The company will follow the procedures outlined in Regulation 31A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The promoters seeking reclassification have provided undertakings confirming their compliance with regulatory requirements, including:

• Not holding more than 10% of the total voting rights in the company
• Not exercising control over the company's affairs
• Not having special rights or shareholder agreements
• Not being represented on the board of directors
• Not acting as key managerial personnel

Market Implications

These developments at Oxygenta Pharmaceutical suggest a potential shift in the company's ownership structure and strategic direction. Investors and market watchers will be keenly observing how these changes might impact the company's future operations and performance.

As the pharmaceutical sector continues to evolve, Oxygenta Pharmaceutical's restructuring could position the company for new opportunities or challenges in the competitive landscape.

The company has not provided specific details about the incoming management or any potential changes in business strategy. Shareholders and stakeholders will likely await further announcements for more clarity on the company's future direction under its new leadership structure.